Strive Asset Management raised $750 million via a merger with Asset Entities. Securities will target struggling biotech firms for cash at a discount. Strive's strategy includes buying distressed bitcoin litigation claims. Biotech index performance is weak, decreasing potential returns. Bitcoin has risen sharply in 2025, drawing renewed interest.